Suppr超能文献

澳大利亚重症监护病房收治的 COVID-19 患者的院内转院和临床结局:一项观察性队列研究。

Inter-hospital transfer and clinical outcomes for people with COVID-19 admitted to intensive care units in Australia: an observational cohort study.

机构信息

Alfred Health, Melbourne, VIC.

Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC.

出版信息

Med J Aust. 2023 Jun 5;218(10):474-481. doi: 10.5694/mja2.51917. Epub 2023 Apr 10.

Abstract

OBJECTIVES

To examine the association between inter-hospital transfer and in-hospital mortality among people with coronavirus disease 2019 (COVID-19) admitted to intensive care units (ICUs) in Australia.

DESIGN

Retrospective cohort study; analysis of data collected for the Short Period Incidence Study of Severe Acute Respiratory Illness (SPRINT-SARI) Australia study.

SETTING, PARTICIPANTS: People with COVID-19 admitted to 63 ICUs, 1 January 2020 - 1 April 2022.

MAIN OUTCOME MEASURES

Primary outcome: in-hospital mortality; secondary outcomes: ICU and hospital lengths of stay and frequency of selected complications.

RESULTS

Of 5207 people with records in the SPRINT-SARI Australia database at 1 April 2022, 328 (6.3%) had been transferred between hospitals, 305 (93%) during the third pandemic wave. Compared with patients not transferred, their median age was lower (53 years; interquartile range [IQR], 45-61 years v 60 years; IQR, 46-70 years), their median body mass index higher (32.5 [IQR, 27.2-39.0] kg/m v 30.1 [IQR, 25.7-35.7] kg/m ), and fewer had received a COVID-19 vaccine (22% v 44.9%); their median APACHE II scores were similar (14.0; IQR, 12.0-18.0 v 14.0; IQR, 10.0-19.0). Bacterial pneumonia (64.7% v 29.0%) and bacteraemia (27% v 8%) were more frequent in transferred patients, as was the need for more intensive ICU interventions, including invasive mechanical ventilation (71.2% v 38.1%) and extra-corporeal membrane oxygenation (26% v 1.7%). Crude ICU (19% v 14.9%) and in-hospital mortality (19% v 18.4%) were similar for patients who were or were not transferred; median lengths of ICU (20.0 [IQR, 11.2-40.3] days v 4.6 [IQR, 2.1-10.1] days) and hospital stay (29.7 [IQR, 18.1-49.6] days v 12.3 [IQR, 7.3-21.0] days) were longer for transferred patients. In the multivariable regression analysis, in-hospital mortality risk was lower for transferred patients (risk difference [RD], -5.0 percentage points; 95% confidence interval [CI] -10 to -0.03 percentage points), but not in the propensity score-adjusted analysis (RD, -3.4 [95% CI, -8.9 to 2.1] percentage points).

CONCLUSIONS

Among people with COVID-19 admitted to ICUs, patients transferred from another hospital required more intense interventions and remained in hospital longer, but were not at greater risk of dying in hospital than the patients who were not transferred.

摘要

目的

研究澳大利亚重症监护病房(ICU)收治的 2019 年冠状病毒病(COVID-19)患者转院与院内死亡率之间的关系。

设计

回顾性队列研究;分析 2020 年 1 月 1 日至 2022 年 4 月 1 日期间参加短期严重急性呼吸综合征发病率研究(SPRINT-SARI)澳大利亚研究的人群数据。

地点、参与者:63 家 ICU 收治的 5207 名 COVID-19 患者。

主要结局指标

主要结局指标:院内死亡率;次要结局指标:ICU 和住院时间以及选定并发症的发生频率。

结果

在 2022 年 4 月 1 日的 SPRINT-SARI 澳大利亚数据库中有记录的 5207 名患者中,328 名(6.3%)在医院之间转院,305 名(93%)在第三波大流行期间转院。与未转院的患者相比,他们的中位年龄较低(53 岁;四分位距[IQR],45-61 岁比 60 岁;IQR,46-70 岁),中位体重指数较高(32.5[IQR,27.2-39.0]kg/m 比 30.1[IQR,25.7-35.7]kg/m ),COVID-19 疫苗接种率较低(22%比 44.9%);他们的中位急性生理学和慢性健康评估 II 评分相似(14.0;IQR,12.0-18.0 比 14.0;IQR,10.0-19.0)。细菌性肺炎(64.7%比 29.0%)和菌血症(27%比 8%)在转院患者中更为常见,需要更强化的 ICU 干预措施,包括有创机械通气(71.2%比 38.1%)和体外膜氧合(26%比 1.7%)。转院和未转院患者的 ICU(19%比 14.9%)和院内死亡率(19%比 18.4%)相似;转院患者的 ICU(20.0[IQR,11.2-40.3]天比 4.6[IQR,2.1-10.1]天)和住院时间(29.7[IQR,18.1-49.6]天比 12.3[IQR,7.3-21.0]天)中位数较长。在多变量回归分析中,转院患者的院内死亡率风险较低(风险差异[RD],-5.0 个百分点;95%置信区间[CI],-10 至-0.03 个百分点),但在倾向评分调整分析中则不然(RD,-3.4[95%CI,-8.9 至 2.1]个百分点)。

结论

在 ICU 收治的 COVID-19 患者中,从其他医院转来的患者需要更强化的干预措施,住院时间也更长,但与未转院的患者相比,院内死亡风险没有增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验